ANAB AnaptysBio Inc revenue, earnings and financials

For the quarter ended March 31, 2026, AnaptysBio Inc reported revenue of $25.6M (down 8.0% from a year earlier), net income of −$52.9M and diluted EPS of −$1.84; over the last four quarters revenue was $232M and net income −$26.8M; for the fiscal year ended December 2025 revenue was $235M, up 157.0% on the year before.

ANAB annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $235M, gross profit n/a, operating income $227M, net income −$13.2M (margin -5.6%), EPS −$0.44
• Fiscal year ended Dec 2024: revenue $91.3M, gross profit n/a, operating income $66.2M, net income −$145M (margin -159.1%), EPS −$4.92
• Fiscal year ended Dec 2023: revenue $17.2M, gross profit n/a, operating income −$164M, net income −$164M (margin -953.7%), EPS −$6.08
• Fiscal year ended Dec 2022: revenue $10.3M, gross profit n/a, operating income −$115M, net income −$129M (margin -1251.3%), EPS −$4.57
• Fiscal year ended Dec 2021: revenue $63.2M, gross profit n/a, operating income −$56.8M, net income −$57.8M (margin -91.5%), EPS −$2.11

ANAB quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $25.6M (down 8.0% year over year), net income −$52.9M, EPS −$1.84
• Quarter ended Dec 31, 2025 (from the annual report): revenue $108M (up 151.1% year over year), net income $49.6M, EPS $1.66
• Quarter ended Sep 30, 2025: revenue $76.3M (up 154.3% year over year), net income $15.1M, EPS $0.52
• Quarter ended Jun 30, 2025: revenue $22.3M (up 102.9% year over year), net income −$38.6M, EPS −$1.34
• Quarter ended Mar 31, 2025: revenue $27.8M (up 286.8% year over year), net income −$39.3M, EPS −$1.28
• Quarter ended Dec 31, 2024 (from the annual report): revenue $43.1M (up 378.8% year over year), net income −$21.8M, EPS −$0.43
• Quarter ended Sep 30, 2024: revenue $30.0M (up 804.7% year over year), net income −$32.9M, EPS −$1.14
• Quarter ended Jun 30, 2024: revenue $11.0M (up 217.1% year over year), net income −$46.7M, EPS −$1.71
• Quarter ended Mar 31, 2024: revenue $7.18M (up 422.5% year over year), net income −$43.9M, EPS −$1.64
• Quarter ended Dec 31, 2023 (from the annual report): revenue $9.01M (up 32.3% year over year), net income −$42.2M, EPS −$1.59
• Quarter ended Sep 30, 2023: revenue $3.32M (up 156.6% year over year), net income −$37.3M, EPS −$1.41
• Quarter ended Jun 30, 2023: revenue $3.46M (up 184.5% year over year), net income −$39.8M, EPS −$1.50
• Quarter ended Mar 31, 2023: revenue $1.37M (up 41.6% year over year), net income −$44.3M, EPS −$1.58
• Quarter ended Dec 31, 2022 (from the annual report): revenue $6.81M (up 573.4% year over year), net income −$26.4M, EPS −$0.93
• Quarter ended Sep 30, 2022: revenue $1.29M (down 93.8% year over year), net income −$33.5M, EPS −$1.18
• Quarter ended Jun 30, 2022: revenue $1.22M (down 96.0% year over year), net income −$32.6M, EPS −$1.15
• Quarter ended Mar 31, 2022: revenue $970K (down 91.4% year over year), net income −$36.3M, EPS −$1.31
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.01M, net income −$32.5M, EPS −$1.19
• Quarter ended Sep 30, 2021: revenue $20.9M, net income −$6.67M, EPS −$0.24
• Quarter ended Jun 30, 2021: revenue $30.0M, net income −$429K, EPS −$0.02

ANAB cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $19.7M, share buybacks $68.6M
• Fiscal year ended Dec 2024: operating cash flow −$135M, share buybacks $456K
• Fiscal year ended Dec 2023: operating cash flow −$121M, share buybacks $50.0M
• Fiscal year ended Dec 2022: operating cash flow −$73.6M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow −$45.9M, share buybacks $0

ANAB balance sheet

• Jun 30, 2026: cash $134M, total assets $317M, total liabilities n/a, shareholders' equity $10.6M
• Mar 31, 2026: cash $248M, total assets $330M, total liabilities n/a, shareholders' equity $12.7M
• Dec 31, 2025: cash $138M, total assets $364M, total liabilities n/a, shareholders' equity $37.2M
• Sep 30, 2025: cash $110M, total assets $353M, total liabilities n/a, shareholders' equity −$29.4M
• Jun 30, 2025: cash $44.3M, total assets $335M, total liabilities n/a, shareholders' equity −$44.7M
• Mar 31, 2025: cash $98.6M, total assets $422M, total liabilities n/a, shareholders' equity $34.0M
• Dec 31, 2024: cash $23.1M, total assets $484M, total liabilities n/a, shareholders' equity $70.9M
• Sep 30, 2024: cash $192M, total assets $493M, total liabilities n/a, shareholders' equity $84.4M

What is ANAB's revenue?

AnaptysBio Inc reported $232M of revenue over its last four quarters, through March 31, 2026.

Is ANAB profitable?

No. AnaptysBio Inc lost $26.8M over the last four quarters.

What is ANAB's EPS?

Diluted earnings per share over the last four quarters were −$1.00; −$1.84 in the latest quarter.

ANAB ownership and insider trades · All stocks